Catch up on the top radiology content of the past week.
|Articles|July 18, 2020
Neurovascular Imaging AI Tool Captures FDA Clearance
Author(s)Whitney J. Palmer
Avicenna.AI’s CINA Head earns 510(k) clearance for emergency room triage of intracranial hemorrhages and large vessel occlusions.
Advertisement
Medical solutions artificial intelligence (AI) company Avicenna.AI secured 510(k) clearance from the U.S. Food & Drug Administration (FDA) this week for its CINA Head neurovascular emergency triage tool.
With a combination of deep learning and machine learning technologies, company officials said, CINA Head can automatically detect and prioritize both intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from CT scans within 20 seconds, alerting the radiologist within their existing system and workflow. It is intended to help triage multiple pathologies.
More than 795,000 strokes occur annually in the United States, leading to more than 100,000 deaths. According to company data, LVO causes up to one-third of stroke-related deaths, and ICH is thought to prompt 10 percent of cases.
Related Content:
“When dealing with a stroke, time is of the essence, and being able to prioritize effectively is critical to saving lives and improving outcomes,” said Peter Chang, M.D., neuroradiologist and Avicenna.AI co-founder. “Not only does CINA Head help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care.”
Based on company test results from 814 cases conducted in more than 250 imaging centers nationwide, CINA’s ICH detection capability was validated with 96-percent accuracy, 91.4-percent sensitivity, and 97.5-percent specificity. The LVO detection capability was validated with 476 cases, leading to 97.7-percent accuracy, 97.9-percent sensitivity, and 97.6-percent specificity.
The company has additional plans for AI tools that can be used in trauma and vascular fields within the next 12 months.
Advertisement
Related to this article
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Catch up on the most well-viewed video interviews from Diagnostic Imaging in September 2026.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
Catch up on the top radiology content of the past week.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
4
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
5